Privia Health Group (NASDAQ: PRVA) insider transactions

In the twelve months to 10 November 2026, executives and directors of Privia Health Group reported 40 open-market sales of 899,644 shares ($22.2m) and 0 open-market purchases, by 4 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Privia Health Group shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
1 September 2026	Ernest Opella Finley	Director	Grant or award	+6,350	—	6,350	Form 4
9 July 2026	Mountcastle David	EVP & Chief Financial Officer	Open-market sale, 10b5-1 plan	−21,275	$27.67	164,853	Form 4
7 July 2026	Mountcastle David	EVP & Chief Financial Officer	Open-market sale, 10b5-1 plan	−600	$27.57	186,128	Form 4
6 July 2026	Morris Matthew Shawn	Director	Option exercise, 10b5-1 plan	+53,722	$2.00	130,373	Form 4
6 July 2026	Morris Matthew Shawn	Director	Open-market sale, 10b5-1 plan	−53,722	$27.24	68,188	Form 4
2 July 2026	Morris Matthew Shawn	Director	Option exercise, 10b5-1 plan	+59,037	$2.00	135,688	Form 4
2 July 2026	Morris Matthew Shawn	Director	Open-market sale, 10b5-1 plan	−59,037	$27.33	76,651	Form 4
2 July 2026	Mountcastle David	EVP & Chief Financial Officer	Open-market sale, 10b5-1 plan	−24,734	$27.50	186,728	Form 4
1 July 2026	Morris Matthew Shawn	Director	Option exercise, 10b5-1 plan	+82,675	$2.00	159,326	Form 4
1 July 2026	Morris Matthew Shawn	Director	Open-market sale, 10b5-1 plan	−45,634	$26.52	113,692	Form 4
1 July 2026	Morris Matthew Shawn	Director	Open-market sale, 10b5-1 plan	−37,041	$26.93	76,651	Form 4
30 June 2026	Morris Matthew Shawn	Director	Option exercise, 10b5-1 plan	+52,823	$2.00	129,474	Form 4
30 June 2026	Morris Matthew Shawn	Director	Open-market sale, 10b5-1 plan	−52,823	$25.72	76,651	Form 4
29 June 2026	Morris Matthew Shawn	Director	Option exercise, 10b5-1 plan	+63,212	$2.00	139,863	Form 4
29 June 2026	Morris Matthew Shawn	Director	Open-market sale, 10b5-1 plan	−63,212	$25.33	76,651	Form 4
26 June 2026	Mountcastle David	EVP & Chief Financial Officer	Option exercise, 10b5-1 plan	+17,196	$2.00	228,658	Form 4
26 June 2026	Mountcastle David	EVP & Chief Financial Officer	Open-market sale, 10b5-1 plan	−17,196	$25.18	211,462	Form 4
26 June 2026	Morris Matthew Shawn	Director	Option exercise, 10b5-1 plan	+88,110	$2.00	164,761	Form 4
26 June 2026	Morris Matthew Shawn	Director	Open-market sale, 10b5-1 plan	−88,110	$25.33	76,651	Form 4
20 May 2026	King David P	Director	Grant or award	+8,463	—	50,775	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Privia Health Group page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.